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Pediatric growth disorders are characterized by the het-
erogeneity of their pathogenesis. The quality of linear
growth, expressed as normal growth rate or height velocity,
is an index of the general health of a child. Classifications of
growth disorders generally divide patients with short stat-
ure into groups of primary or secondary disorders [1,2] and
those with so-called idiopathic short stature, a broad
category that includes the healthy short child in whom no
specific pathological cause has been identified [3].
Management of the child with a disorder of growth is a
fundamental responsibility of pediatric healthcare pro-
fessionals. Short stature may present clinically to any of the
three levels of child health. In primary care, routine
assessment of weight and height may detect insufficient
growth and justify referral of the child for further assess-
ment. In secondary care, the pediatrician needs to under-
stand the differential diagnosis of short stature and be
familiar with the key principles of clinical and laboratory
assessment. Finally, the tertiary pediatrician, working in a
specialist pediatric endocrinology unit to whom the child
may ultimately be referred, needs to acquire experience in
detailed endocrine assessment, consideration of thera-
peutic options, approaches to growth-promoting therapy,
specifically with human growth hormone (hGH) and initia-
tion and monitoring of hGH therapy.
The optimal management of the child with short stature
in the GCC countries presents interesting challenges in
terms of ethnic, socio-economic, and genetic diversity.
Agreement exists that early diagnosis and treatment,
particularly when hormone therapy is appropriate, leads to
a greater benefit for the patient and will be linked to an
improved adult height prognosis in subjects treated with
hGH [4,5].
This article will review current clinical procedures,
identify important challenges and, where possible, use
evidence-based data to provide key recommendations for
best practice in the management of growth disorders. The
manuscript will be organized in the following way: A
recent review of clinical practice in GCC countries [6] will
be summarized, followed by sections that address issues
that follow the child identified to have short stature by
screening in primary care, criteria for referral to the
secondary pediatrician, basic clinical and laboratory as-
sessments, investigations of the GH-IGF-1 axis in a
specialist unit and initiation and management of hGHtherapy. Additional topics of adherence to hGH therapy
and transitional care of the patient with GH deficiency
will be covered.
2. Clinical practice in patients with GH
deficiency (GHD) receiving hGH therapy in GCC
countries
A meeting of experienced pediatric endocrinologists from
four GCC countries was convened in 2011, and the pro-
ceedings, published in 2014 [6], concluded that most GCC
experts adhered to international guidelines for hGH therapy
in patients with GH deficiency (GHD) [7]. However, no
agreement was reached on a single optimal approach to
hGH therapy. Lack of clarity related to the diagnosis of GH
deficiency, and the absence of a common approach to
assessment of poor and good growth responses and their
respective definitions was reported. Poor adherence to hGH
was identified as a key area of concern. It was concluded
that greater standardization of clinical practice with unifi-
cation of protocols across the GCC countries was needed to
optimize hGH therapy [6].
2.1. Height screening for short stature in primary
care
2.1.1. Current procedures
Height screening currently exists to a variable degree in
normal populations or in primary child health clinics across
the GCC countries. This practice is consistent with the
practice of population height measurement to identify
short stature, which varies widely across countries and
cultures [8,9]. Height screening is available in the majority
of schools in the UAE and is mandated by the health au-
thority in Abu Dhabi and the Ministry of Health in Dubai.
Height and weight measurements were recorded during
medical examinations as part of the Pediatric Kuwait
Nutrition Surveillance System (PKNSS), providing data on
stunting and wasting in children under the age of 60 months
under the auspices of the Kuwait Ministry of Health. Mea-
surements were performed during mandatory routine
vaccination examinations. Primary care nurses were trained
in measurement techniques, and lengths/heights were
plotted on WHO growth charts published in 2006 [10], which
are ideally suited for growth monitoring in children under
five years of age in a multi-ethnic population [11]. A report
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length/height 2 SDS) in 3860 subjects varied from 8.4% in
infants under six months of age to 1.7% in one- to two-year-
old children and 3.1% in four- to six-year-old children [12].
Length/height 2 SDs was used as an indication for referral
to a general pediatrician. These data are clearly of value;
however, further analysis is required to determine the
percentage of the short children who were subsequently
demonstrated to have a pathological cause for their short
stature.
2.1.2. Recommendations
In GCC countries, WHO charts are considered to be best
suited to detect children with failure to thrive or growth
failure during the first two years of life. The Saudi growth
charts established in 2007 [13] would generally be prefer-
able to the WHO charts for use in Saudi Arabia. They are
also preferable to the 2000 CDC charts, which, if used,
would result in unnecessary referrals for short stature and
undernutrition [14].
An ideal height screening program in primary care should
have sufficient sensitivity to detect pathology and sufficient
specificity to prevent the referral of completely healthy
subjects [15]. Individual studies have measured populations
of healthy pre-school or school children and reported a
prevalence of pathological short stature in subjects with
height 2 SDS to be approximately 5% [16e18]. However,
the performances of most programs and particularly their
economic consequences have not been critically appraised
[8,9].
Auxological criteria are required for referral of short
stature from primary to secondary care (Table 1). In
Europe, studies in the Netherlands based on referral from
routine child health clinics to secondary care have recom-
mended evidence-based criteria. Grote et al published
guidelines for a protocol including the performance of the
best screening parameters in terms of sensitivity (true-
positives) and specificity (false-positives) [15]. In 0e3-year-
old children of normal birth weight, height SDS 3 or height
SDS 2 on two or more occasions within one year gave the
best sensitivity for a positive diagnosis with a low false-
positive rate. For children aged 3e10 years, the combina-
tion of height, which is short for parental target height
(TH), i.e., height SDS >1.6 below TH SDS and height SDS
2.5 and a change in height SDS >1 over an undetermined
time interval, detected 85.7% of children with Turner syn-
drome and 76.5% of children with other growth disorders
[15]. An updated definition of TH is used [19]; however, inTable 1 Criteria for referral of short children from primary to
Infants from birth to three years of age
 Height SDS 3 or
 Height SDS 2 (3rd percentile) on two or more occasions withi
Children aged three to 10 years
A combination of:
 Height that is short for parental target height (TH), i.e., heigh
 Height SDS 2.5
 Change in height SDS >1 over an undetermined time interval (m
Note: For TH calculation, see Ref. [19] although mid-parental heightprimary and secondary care, the mid-parental height can
be used. The false-positive rate was low. Analysis of these
criteria was the basis for a recently updated algorithm for
referral of children identified to be of short stature in pri-
mary care [20].
2.2. Investigation of short stature in secondary
pediatric care
2.2.1. Current procedures
The responsibility for clinical assessment and initial in-
vestigations in children with short stature largely rests with
secondary pediatricians, to whom infants or children
identified as being short in primary care settings will be
referred. There is current concern by GCC specialists that
the education, knowledge, and experience of general pe-
diatricians in the subject of childhood growth and growth
disorders are insufficient. This deficiency should be iden-
tified as a priority in terms of medical education, which is
needed for pediatricians to appreciate the importance of
height as a biological index of general health. Pediatricians
also have the responsibility to distinguish causes of poor
growth such as failure to thrive, malnutrition, and chronic
illness, e.g., gastrointestinal disorders, for which hormonal
investigations are generally not required, from true endo-
crine disorders, which should be referred to pediatric
endocrinology specialists.
2.2.2. Recommendations
Medical education is required to emphasize the basic
disciplines of clinical assessment, i.e., history taking and
physical examination, techniques of height measurement,
and the use of growth charts together with knowledge of
the differential diagnosis of short stature. In children with
significant short stature, i.e., the auxological criteria for
referral (see above), important baseline investigations
should be performed to exclude non-endocrine pathology.
Recently, debates have taken place concerning baseline
investigations contributing to the diagnosis of pathological
short stature. In 2008, a consensus statement on the man-
agement of idiopathic short stature (ISS) patients recom-
mended a panel of laboratory screening investigations for
the short child [21]. A similar approach has been endorsed
by other groups [2,22]. Regional differences in the inci-
dence of certain disorders may alter the frequency of
certain specific investigations. In 2013, a challenge to this
principle of screening investigations in patients ‘for whom
the history and physical exam do not suggest a particularsecondary care [15].
n one year
t SDS >1.6 below TH SDS
inimum four months)
SDS can be used.
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nati Children’s Hospital Endocrinology Clinic reported that
screening tests in ‘asymptomatic short patients’ gave little
diagnostic information and were not cost-effective, justi-
fiably challenging the practice of ‘blanket screening’ in
short children. However, in the context of secondary pe-
diatrics in GCC countries, it is unlikely that pediatricians
would have the experience to exclude disorders such as
celiac disease, Crohn’s disease, or mosaic Turner syndrome
without performing baseline investigations. Our recom-
mendations for clinical assessment and baseline in-
vestigations in short stature children are shown in Table 2.
2.3. Investigation of the growth hormone-IGF-1 axis
2.3.1. Current procedures
The GH-IGF-1 axis is the primary endocrine axis that regu-
lates linear growth, and its investigation is indicated in any
child in whom other significant causes of short stature have
been excluded. In GCC countries, GH-IGF-1 axis in-
vestigations are generally performed in specialist or ter-
tiary units under the care of a pediatric endocrinologist.
The specialist has the responsibility to confirm the auxo-
logical status of the patient using WHO, CDC or Saudi
growth charts as appropriate. General pediatric in-
vestigations also need to be checked, and disorders such as
Turner syndrome, SGA, dysmorphic syndromes, and chronic
illnesses must be excluded.
A report from GCC specialists has stated that no
consensus was reached on the optimal procedure for
assessing the functional integrity of the GH-IGF-1 axis [6].
Essentially two forms of investigation comprise this
assessment; firstly, baseline measurements of the growth
factors IGF-1 and IGFBP-3 and secondly GH stimulation
tests. The IGF-1 generation test may be needed to assess
peripheral sensitivity to GH.Table 2 Clinical assessment and laboratory investigations rec
stature [2,5].
Clinical assessment
 History: family history, inquiry about consanguinity, parental h
systematic inquiry for chronic symptoms
 Accurate height measurement using wall stadiometer, weight,
with parental height percentiles
 Physical examination of systems
 Examination for dysmorphic features
Laboratory investigations
 Complete blood count
 Renal function
 Liver function
 ESR
 Calcium, phosphorus
 Alkaline phosphatase
 Bone age
 Skeletal X-rays (when body disproportion is present)
 Tissue t
 IgA
 IGF-1 (w
 Free T4
 Karyotyp
ESR, erythrocyte sedimentation rate; IgA, immunoglobulin A; IGF-1, in
stimulating hormone; FSH, follicle-stimulating hormone.For serum IGF-1 measurements, normal ranges for sex
and age are provided by laboratories performing the assays.
Values 2 SD are considered to be abnormal, but IGF-1 SDS
calculations have not been equally adopted in clinical
practice in the GCC region. The difficulty of interpretation
of IGF-1 levels in infants under three years of age is
recognized, and IGFBP-3 may be of greater value for diag-
nosis of GH deficiency in these subjects [24]. Interpretation
of IGF-1 in children with low BMI may also be difficult.
IGFBP-3 determination is performed sporadically
throughout GCC countries. The IGF-1 generation test may
be performed in children with low IGF-1 and normal or
elevated GH secretion, although its interpretation may be
problematic [25].
A range of GH stimulation tests is used, including cloni-
dine, arginine, glucagon, and insulin. Priming of the GH
stimulation test with sex steroids is performed variably, and
determination of overnight physiological GH secretion is
not performed. The cut-off GH level for diagnosis of GH
deficiency is also variable between centers from 8 to
10 mg/L. In some centers, specialist pediatric endocrinology
nurses support patient care; however, the GH tests are
usually performed by medical staff. Pituitary MRI scans are
performed in patients diagnosed with GH deficiency.
2.3.2. Recommendations
The assessment of the GH-IGF-1 axis to exclude or confirm
GH deficiency is recognized to be problematic, and the
approach to this investigation is controversial (Table 3)
[3]. Detailed clinical and auxological assessment of the
patient is essential, and in particular, a subnormal growth
rate is a strong guide to GH deficiency or resistance. If
available, baseline serum IGF-1 is then determined in a
laboratory using a high quality standardized IGF-1 assay
[26], ideally on 2e3 occasions to exclude nutritional var-
iations. Normative IGF-1 [27] or IGFBP-3 [28]ommended in children referred to secondary care for short
eights, birth weight, length of gestation,
BMI, plotting of height on growth chart compared
ransglutaminase
hen available)
, TSH
e or FSH (<2 and >9 years) if not available (in females only)
sulin-like growth factor 1; Free T4, free thyroxine 4; TSH, thyroid-
Table 3 Recommended assessment of the GH-IGF-1 axis.
Clinical assessment
 Confirmation of auxological status
 Confirmation of investigations excluding non-GH deficient short stature, e.g., karyotype (in females)
 Exclusion of dysmorphic features of known short stature syndromes
 Exclusion of skeletal dysplasia
Laboratory assessment
 IGF-1  2e3 samples with comparison to normative data for age and sex
 IGFBP-3 (optional)
 GH stimulation test
 Priming with sex steroids in boys > 11 years and girls > 10 years and not in established puberty
 Cut-off for GH deficiency 6.7 mg/L using assay with IS 98/574
 Genetic sequencing of candidate genes or whole exome sequencing (when history and phenotype suggests genetic origin)
Hypothalamic-pituitary MRI scan in patients with GH deficiency
GH, growth hormone; IGF-1, insulin-like growth factor 1; IGFBP-3, Insulin-like growth factor binding protein 3; IS 98/574, International
Recombinant Human GH Standard 98/574.
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literature or from the local laboratory must be used for
their interpretation. A plasma IGF-1 at or around the mean
for age or in the upper half of the normal range would
make a diagnosis of GHD very unlikely [3], and such a
patient would not require a GH stimulation test. On the
other hand, a low serum IGF-1 for age (2 SDS) in the
presence of auxological abnormalities would indicate a
relatively high likelihood of GH deficiency, which should
then be confirmed by a GH stimulation test. A number of
commercial assays are available to facilitate the conver-
sion of serum IGF-1 values to SDS scores [29].
A GH stimulation test should ideally have high repro-
ducibility, generate a strong stimulus for GH secretion,
and have a favorable safety profile [7]. The exercise test
has no adverse effects, but its positive predictive value is
low. A traditional cut-off GH value of 10 mg/L for GH
deficiency during the GH stimulation test has been used;
however, an international consensus has recommended
that if a GH assay using a polyclonal anti-GH antibody is
calibrated against the international standard [IS] (IS 98/
574), a cut-off of 6.7 mg/L is appropriate throughout
childhood and early adolescence [26]. The Growth Hor-
mone Research Society consensus statement recommends
two GH stimulation tests to confirm the diagnosis of GH
deficiency [7]. In our opinion, a single GH test combined
with basal IGF-1 and interpreted together with clinical and
auxological results will provide sufficient data to exclude
or confirm GH deficiency.
Most pediatric endocrinologists use sex steroid priming
immediately before the GH stimulation tests in boys who
are older than 11 years of age and girls who are older than
10 years of age who are not in advanced puberty [7].
Choices for priming are a depot testosterone injection
100e125 mg five days before the GH test, ethinyloestradiol
100 mg daily for three days, or stilboestrol 1 mg twice daily
for the two days before the test. An MRI scan of the
hypothalamic-pituitary region should be performed in pa-
tients diagnosed with GH deficiency. This is particularly
important in the infant presenting with congenital hypopi-
tuitarism [30]. In children with short stature who have apersistently low IGF-1 level, but GH secretion is normal, the
IGF-1 generation test (IGF-1GT) may give information
relevant to GH sensitivity. However, the IGF-1GT has been
critically appraised and is likely only to be of benefit if the
patient has extreme rather than partial GH insensitivity
[25]. Genetic investigations may identify novel or estab-
lished causes of GH deficiency, and both candidate gene
and whole exome sequencing are available in specialist
laboratories [31,32].
2.4. Growth hormone therapy
2.4.1. Factors influencing individualization of hGH
therapy
2.4.1.1. Current procedures. In GCC countries, the
growth disorders generally treated with hGH have been
approved by Food and Drug Administration (FDA). Some
disorders that are currently not approved such as achon-
droplasia and 3-M syndrome may also be treated. The doses
of hGH used are usually doses recommended by the US
Pediatric Endocrine Society [33]. GCC experts are generally
satisfied with the range of therapies available; however, a
common approach to the individualization of hGH therapy
has not been developed, and the formal use of growth
prediction models has not been adopted.2.4.1.2. Recommendations. Growth hormone deficiency
in children covers a wide range of GH secretory abnormal-
ities, ranging from extreme deficiency in congenital hypo-
pituitarism to mild or partial deficiency, which normalizes
during exposure to sex steroids in puberty. A continuum
model of GH-IGF-1 axis defects can be defined in which GH
sensitivity on the X-axis scale ranging from high in the
severely GH deficient subject to low or non-existent in the
GH-resistant subject can be plotted against a range of GH
secretion on the Y-axis [22,34] (Fig. 1). It is clear from the
model that patients with severe GH deficiency have greater
sensitivity and responsiveness to hGH therapy than patients
with mild or partial deficiency. This variation in
responsiveness is demonstrated in clinical practice, where
Figure 1 The continuum model of growth hormone-IGF-1
axis defects, showing variation in growth hormone respon-
siveness in different growth disorders compared to severe GH
deficiency. Growth hormone (GH), idiopathic short stature
(ISS), Turner syndrome (TS), short stature related to birth size
small for gestational age (SGA).
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superior growth responses compared to milder cases
(peak GH 3e10 mg/L) [35] and is also a key finding in
analysis of data used to construct mathematical growth
prediction models [36e38].
The variation in GH responsiveness is even more marked
when non-GH deficiency disorders such as Turner syndrome
and short stature secondary to SGA are treated with hGH
[22] (Fig. 1). When GH-deficient patients are treated with a
fixed dose of GH calculated for body weight or surface area,
the mean response and stature at adult height may appear
satisfactory, but a considerable variation in responses ex-
ists [39]. This variation is reduced when the hGH dose is
individualized for each patient, depending on the variables
predicting the likely response [40]. The key variables are
diagnosis of the growth disorder, age at start of therapy,
peak GH during a GH stimulation test in GH deficiency,
height SDS compared with mid-parental height SDS, and
dose of hGH. When hGH therapy is initiated, all of these
factors should be taken into consideration to calculate the
dose (Fig. 1).
2.4.2. Responses to hGH therapy in GH deficiency
2.4.2.1. Current procedures. General agreement exists in
the GCC countries that GH deficiency is the most common
indication for hGH therapy. International guidelines for
initiation and monitoring of therapy were followed [7]. A
starting hGH dose of 25 mg/kg/day was generally used,
irrespective of the severity of the GH deficiency and
might be increased to 50 mg/kg/day in patients with
disappointing growth responses [6]. Patients were
monitored every three or four months during the first
year of therapy and thereafter every six months. A
common approach was not available for the selection of
the hGH dose and, in particular, an agreement was
lacking on the definition of a good or poor response. The
quality of growth response during the first year of hGH
therapy was, however, recognized to predict long-termbenefits in terms of adult height following completion of
therapy.
2.4.2.2. Recommendations. Evidence-based data sup-
porting the key factors predicting growth response during
the first and second years of hGH therapy in GH deficiency
should be considered when the starting dose of hGH is
selected. Key predicting factors are severity of GH defi-
ciency, age of the patient, and distance between the pa-
tient’s height SDS and mid-parental height SDS [38].
Subjects with multiple pituitary hormone deficiencies
experience better growth than individuals with isolated
GH deficiency [41]. The starting dose of hGH should
follow EMA and US Pediatric Endocrine Society guidelines
of 23e39 mg/kg/day, i.e., 0.18e0.25 mg/kg/week [33,42].
Patients with severe GH deficiency, i.e., peak GH
<3 mg/L, and patients with multiple anterior pituitary
hormone deficiencies require hGH doses at the lower end
of the recommended range, whereas patients with mild
or partial GH deficiency require doses at the upper end of
the range [38]. The increase of hGH dose during puberty
is not recommended [33].
Following the initiation of hGH therapy, there is a need
to define a poor or unsatisfactory response and to prevent
or correct it by optimizing treatment within accepted
guidelines. Poor responses to hGH are relatively common
[35], and recognition of a poor response is an indication for
action, either to modify the therapy or to review the pri-
mary diagnosis [43]. Unfortunately, no international
consensus exists on the definition of a poor first-year
growth response. Bakker et al suggested that GH-deficient
patients with a first-year height velocity less than a mean
HV 1.0 SD for that sex and diagnosis should be labeled as
poor responders [44]. Similarly, Ranke argued that a poor
response equals a gain in height SDS of <0.4 in a patient
with severe GH deficiency and an increase in height SDS of
<0.3 in patients with less severe GH deficiency, girls with
TS or SGA subjects [38]. A change in height SDS >0.5 during
the first year of therapy generally indicates that the patient
is experiencing catch-up growth. In contrast, a change in
height SDS <0.3 indicates a poor response [43]. Measure-
ment of IGF-1 concentration is recommended for children
with GH deficiency treated with hGH, with the aim of
normalizing serum IGF-1 concentrations. However, evi-
dence is lacking that supports the value of IGF-1 monitoring
for safety in children and the lack of any data to indicate a
safe upper limit for serum IGF-1 concentrations [45].
2.4.3. Responses to hGH therapy in Turner syndrome,
short stature related to SGA and idiopathic short stature
2.4.3.1. Current procedures
2.4.3.1.1. Turner syndrome. In GCC countries, Turner
syndrome is accepted as an indication for hGH therapy. In
patients with the classical Turner syndrome phenotype and
chromosomal abnormality, hGH therapy may be started as
young as 1e2 years of age, with height SDS 2 being
considered as an indication for therapy. A pharmacological
dose of hGH 40e50 mg/kg/day is used, and the dose may be
adjusted after six months if no change in height SDS is seen.
The definition of a satisfactory response is an increase in
height SDS of >0.5 during the first year of therapy. Growth
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until adult height is reached. Estrogen replacement therapy
is normally initiated at 11e12 years of age. Transitional
care to adult services is implemented with multi-
disciplinary support. No specific adult Turner syndrome
units have been reported.
2.4.3.1.2. Small for gestational age. Short stature
related to birth size small for gestational age (SGA), defined
as birth weight and/or length 2 SD for gestational age, is a
licensed indication for hGH therapy approved by both the
FDA and EMA. In GCC countries, it appears that many chil-
dren with short stature related to SGA are missed, and
relatively few receive hGH therapy. However, this is a
global finding with far fewer subjects presenting and
receiving therapy than are statistically eligible [46]. The
average age for starting hGH therapy was reported to be
between seven and nine years [47]. The population of SGA
subjects in GCC countries is of particular interest related to
an increased prevalence of genetic causes such as 3-M
syndrome [48] and IGF-1 and IGF-1 receptor mutations
[49]. No consensus currently exists on the approach to the
management of short stature related to SGA.
2.4.3.1.3. Idiopathic short stature. Idiopathic short
stature (ISS) is not a specific diagnosis. It is a descriptive
term used to define children who are short, i.e., height
2 SD, with normal birth weight, absence of chromosomal
defects, no dysmorphic features or chronic illnesses, and no
identified endocrine abnormality [50]. The term ISS,
therefore, describes a heterogeneous group of children
with many unidentified causes of short stature [21]. The
approach to the management of ISS and specifically hGH
therapy in ISS subjects remains controversial, with FDA
approval for hGH being granted in 2003. In contrast,
approval has not been given by the EMA despite numerousTable 4 Recommended approach and hGH treatment regimens
stature (ISS).
Turner syndrome SGA (bir
Factors predicting
response [55]
 hGH dose
 Age
 Weight SDS
 Oxandrolone
 hGH d
 Age
 Weigh
 MPH S
hGH dose (mg/kg/day) 50 35a
67b
Starting height (SDS) e 2.5a
2.5b
Starting age (years) e 4a
2b
Key comments  Early diagnosis
 Oxandrolone <0.06 mg/kg
from 8 to 10 yr
 Sex steroids at
physiological age
 Transition essential
 Early d
 Increa
with h
 Start h
before
SGA, Small for gestational age; SDS, Standard deviation score; MPH, M
a UK National Institute for Health & Care Excellence (NICE)/Europe
b FDA, (US Food and Drug Administration (FDA) guidance.applications by pharmaceutical companies [21]. Although a
consensus approach to the diagnosis or treatment of ISS in
GCC countries has not been established [6], it appears that
FDA rather than EMA guidelines are generally followed,
with approximately 20% of hGH-treated children having ISS
as reported from Kuwait [51] and the UAE [52].
2.4.3.2. Recommendations
2.4.3.2.1. Turner syndrome. As a specific disorder,
albeit with a range of X-chromosome defects and significant
phenotypic heterogeneity, Turner syndrome is a licensed
indication for hGH therapy. The beneficial pharmacological
effect of hGH therapy on growth in Turner syndrome pa-
tients is now established [53], and a general agreement
exists that the hGH dose of choice should be approximately
50 mg/kg/day [54]. Key factors predicting the growth
response to hGH are the dose of hGH, a young age at
initiation, and the duration of therapy [53e55] (Table 4).
Children started on hGH before the age of four years are
particularly responsive [56]. A small additional gain in adult
height (2.3e4.6 cm) has been reported if the mild androgen
oxandrolone (0.03e0.05 mg/kg/day) is given starting at
8e10 years of age in addition to hGH [57].
Debate remains concerning the optimal regimen for es-
trogen replacement in girls or adolescents with Turner
syndrome. Quigley et al [58] have recently presented
compelling results showing advantages in terms of growth,
pubertal development, and cognitive function when very
low-dose estrogen replacement was commenced from the
age of five years. Whether a regimen such as this or es-
trogen commencement at the physiological age of puberty
is chosen, agreement exists that delaying sex steroid
replacement until the mid-teen years, with the aim of
prolonging and improving hGH-induced height gain, isfor patients with Turner syndrome, SGA and idiopathic short
th weight/length  2 SD) ISS
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detailed management of gonadal dysgenesis is beyond the
scope of this review.
2.4.3.2.2. Small for gestational age. The criteria for
hGH therapy in SGA subjects differ between the FDA and
EMA approval guidelines (Table 4). However, there is
agreement that hGH can induce significant gain in adult
height. Research data has demonstrated rapid height gain
in young, pre-school SGA subjects treated with hGH [60],
and early diagnosis and initiation of therapy is strongly
recommended [47]. Catch-up growth occurs more rapidly
when an hGH dose of approximately 67 mg/kg/day is used
[61] and maintained for up to four years [62,63]. However,
the dose of hGH recommended in the EMA license is 35 mg/
kg/day, which also induced significant adult height gain [46]
(Table 4). This was further increased marginally by the
addition of a GnRH analogue to suppress puberty [64].
Convincing evidence is available suggesting that a delay in
hGH treatment until less than two years before the physi-
ological onset of puberty compromises adult height gain
[65].
2.4.3.2.3. Idiopathic short stature. In 2003, the FDA
approved ISS as a licensed indication for hGH therapy for
patients with height 2.25 SD and a reduced adult height
expectation. No agreement exists on the optimal thera-
peutic approach to such patients; however, because these
patients do not have GH deficiency, a pharmacological dose
of approximately 50 mg/kg/day has been recommended
[21,50,66] (Table 4). In a recent Nordic study [35], no dif-
ference was observed in the first-year growth response to
hGH in patients with mild GH deficiency (peak GH 3e7 mg/
L) and with ISS (peak GH >7 mg/L). Age at the start of
therapy and dose of hGH are the two key factors predicting
growth response [4]. However, as the quality of response in
ISS is unpredictable, and the rate of poor response is 30%e
40% [35], an approach to the family explaining this infor-
mation is important. The first-year response will correlate
with long-term benefits; therefore, assessment of change in
height SDS at the end of the first year of hGH therapy is
essential [66]. In patients who show a change of height
<0.3 SDS, discontinuation of treatment is recommended
[43]. Some slight additional gain in pubertal growth may be
achieved by the addition of a GnRH analogue to hGH. In this
case, the analogue should be commenced in early puberty
and continued for a minimum of two years [67].
2.5. Transitional care of the GH-deficient patient
after completion of linear growth
2.5.1. Current procedures
In the GCC countries, the concept of transitional care for
the transfer of patients with GH deficiency from pediatric
to adult endocrine care is recognized to be important.
Agreement exists with the guidelines published by the
American Association of Clinical Endocrinologists [68];
however, their implementation has proven to be difficult in
practice. The establishment of transitional care services is
recognized as an unmet clinical need. Currently, clinical
care is organized on the basis of ‘transfer’ to adult endo-
crinology, rather than through a process of ‘transition’
involving collaboration of pediatricians and adultspecialists. Two obstacles that have been identified for
optimal care are first, the relatively young age, for example
12e14 years of age, when a patient is required to leave
pediatric care and secondly, the reluctance of some adult
endocrinologists to take over the care of a patient receiving
hGH therapy because of the administrative load linked to
this treatment. Joint transition clinics have not been
established, and endocrine specialist nurses are generally
not involved in the care of adolescent patients. Patients
with diabetes mellitus are considered to have priority over
patients with other endocrine disorders.
2.5.2. Recommendations
Transitional care of the adolescent and young adult patient
at completion of linear growth was brought into focus by
the establishment of the adult GH deficiency syndrome as a
distinct clinical and endocrinological entity [69]. Ran-
domized studies on the effects of discontinuation of hGH
replacement in the GH-deficient adolescent demonstrated
unequivocally that bone mineral content [70] and body
composition [71] became impaired. Continued hGH
replacement until the age of acquisition of peak bone mass
and full physical maturity, i.e., at approximately 25 years
of age, is necessary to complete physiological somatic
development. Studies of quality of life (QoL) during the
transitional period indicated that although overall baseline
QoL was not compromised in severely GH-deficient pa-
tients, dimensions related to age-specific psychological
problems were significantly worse than in healthy subjects
and appeared to positively respond to hGH treatment [72].
Following these studies, it became clear that a structure
of care was required to manage the endocrine re-
quirements of the GH-deficient patient between pediatric
and adult services. This need was recognized by a dedi-
cated consensus statement that set out the principles, re-
quirements and practical details of a transitional care
service [73]. Following completion of linear growth, GH
secretion needs to be reassessed, ideally using an insulin or
glucagon stimulation test. Growth hormone replacement
will be limited to patients with severe GH deficiency, i.e., a
peak GH level <3e5 mg/L. Further results on the imple-
mentation of transitional care have been published [74].
These results are summarized in Table 5.
2.6. Adherence to hGH therapy: prevention and
management of poor adherence
2.6.1. Current procedures
Adherence to hGH therapy and the prevention of poor
adherence were topics that have been clearly prioritized by
GCC specialists. Poor adherence was considered to be the
most likely cause for a suboptimal growth response in GCC
countries [6]. The link between poor adherence and poor
growth responses to hGH, now well documented in the
literature [75,76], were clearly identified. The most
frequently advocated steps to improve adherence were
first, the initiation of a motivational conversation with the
patient and secondly, the use of an electronic injection
device that would record the number of doses adminis-
tered. A strategy to address the issue of adherence to hGH
remains to be implemented.
Table 5 The principles and requirements of transitional care to meet the needs of the GH-deficient patient following
completion of linear growth.
Requirements:
 Development of an amicable and collaborative working relationship between the pediatric and adult endocrinologist
 Clinical and academic interest of the adult endocrinologist to take responsibility for the young adult patient with severe GH
deficiency
 Understanding that somatic and skeletal development is not complete until the age of 25 years and that the GH-IGF-1 axis is
necessary to achieve this
Organization:
 Joint consultations in either the pediatric or adult setting to agree on priorities for investigations, e.g., DEXA scan, reas-
sessment of GH secretion
 Following demonstration of GH deficiency, an agreed protocol for reintroduction of hGH therapy
 Assessment of pituitary function, both hormonal and imaging, to ensure optimal puberty, thyroid and adrenal function
 Ideally, close liaison between pediatric and adult endocrinology specialist nurses
Benefits:
 Seamless patient care with transfer to the adult service at an agreed age and following an agreed protocol of care
 Educational advantages for both pediatrician and adult specialist with opportunities for productive collaborative research
GH, growth hormone; hGH, human growth hormone; IGF-1, insulin-like growth factor 1.
Figure 2 Key stages in the implementation of a program to
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Adherence to any chronic therapy is a challenge for the
patient and the treating physician. Treatment with hGH is
both invasive and psychologically demanding because of its
long-term time frame. Evidence suggests that poor adher-
ence to hGH is common; however, this topic is frequently
ignored by the medical team responsible for the patient
[77]. It is simpler to pretend that poor adherence does not
exist than to take steps to address it. The most common
reasons have recently been reviewed [78] and are summa-
rized in Table 6.
Addressing the topic of adherence requires that a basic
organizational structure be introduced into the growth
disorders outpatient clinic. Clearly the head of the clinic
needs to be fully committed to this activity. A single health
care professional (HCP), who could be a nurse, doctor
or psychologist, should assume primary responsibility for
issues related to adherence and develop an initial and on-
going relationship with the patient before and during hGH
therapy. The technique of non-confrontational interviewing
and encouragement of the patient that will be carried out
by this HCP requires training and, once implemented, adds
time to the outpatient consultation, which is an additional
reason why adherence is frequently ignored. A summary ofTable 6 The most common reasons for poor adherence to hGH
 The child’s and care-giver’s lack of understanding of the prima
 Adolescence
 The length of treatment anticipated
 Implications of poor adherence regarding growth response
 Inadequate support and monitoring by healthcare providers inc
 Pain and discomfort of injections
 Fear of needles
 Lack of choice of injection device and/or complicated devices
 Parental lifestyles and inadequacy of support of the child
 Inconvenience of injection schedule
 Dissatisfaction with the growth responsethe key steps involved in the implementation of an adher-
ence program is shown in Fig. 2.
The establishment of such a program will be of consid-
erable value to patients receiving hGH therapy and willtherapy.
ry disease
luding inconsistent contact
address the subject of adherence to pediatric hGH therapy.
100 A.S. Al Herbish et al.bring rewards to the medical and nursing team involved in
their management. A program which addresses communi-
cation skills of HCPs, adherence and the delivery of
consistent advice may well be beneficial outside the field of
hGH therapy. The introduction of such programs can
contribute to cost-effective services, especially in the
current climate of value-based health care (Fig. 2).
3. Conclusion
The diagnosis and management of growth disorders is a
challenging field, particularly in the context of a wide and
multi-ethnic geographical area, such as what exists in the
GCC countries. This review aimed not to be critical, but
constructive. A widespread commitment exists extending
from primary to tertiary pediatric health care to address
the current gaps in clinical procedures and to work
toward the goal of best practice. The recommendations for
diagnosis and treatment of growth disorders that have been
described in the review are attainable, but by definition,
they are also challenging. The authors, representing four
key GCC countries, have demonstrated their determination
to show leadership through clinical example and education
to achieve optimal standards in this rich and exciting field
of clinical pediatrics.
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